Contribution of norketamine to ketamine-induced antinociception,

INTERVENTION: Trade Name: Ketanest Product Name: ketanest Pharmaceutical Form: Intravenous infusion INN or Proposed INN: KETAMINE CAS Number: 6740881 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5‐25 Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use CONDITION: Pain induced in healthy volunteers ; MedDRA version: 9.1 Level: LLT Classification code 10066714 Term: Acute pain PRIMARY OUTCOME: Main Objective: To assess the contribution of norketamine to ketamine's antinociceptive properties Primary end point(s): Pain relief; Response to cognitive tests; sedation; cardiovascular changes Secondary Objective: To assess the contribution of norketamine to ketamine's cognitive effects INCLUSION CRITERIA: Healthy male volunteers in the age of 18‐45 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range